Protease inhibitor based triple therapy in treatment experienced patients
|
|
- Sarah Sutton
- 6 years ago
- Views:
Transcription
1 Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber und Studienzentrum am Checkpoint, Berlin
2 Virologic response patterns on dual therapy with Peg Interferon plus ribavirin in HCV type 1 Baseline Treatment Null Nonresponder HCV RNA Partial responder Breakthrough Relapser HCV RNA undetectable Detection limit Sustained responder (SVR) < 15 IU/ml Time 6 Months 1. Strader D, et al. Hepatology 24; 39: Farci P, et al. PNAS 22; 99: 381
3 Innate immunity and HCV Interferon signaling and Mechanismens of Interferon nonresponsiveness Ineffective upregulation of ISGs Pre-activated IFN system IFN system not activated Induction of the endogenous IFN system in the liver is not only ineffective in clearing viral infection, but also prevents response to peg IFNa and ribavirin therapies Heim M. J Hepatol 213; 58: 564
4 Early virologic response patterns during HCV protease inhibitor monotherapy Telaprevir monotherapy Median Log HCV RNA Placebo (n = 6) Breakthrough (n = 13) Plateau (n = 8) Continuous decline (n = 7) Time (Days) Sarrazin C, et al. Gastroenterology 27
5 Individual response to Peg IFN/ribavirin: Implications for the use of Protease inhibitor (PI) based triple therapy 7 6 Peg IFN alpha RBV Null response (<1 log decline at week 4) Risk of a functional PI mono therapy Log HCV RNA Partial reponse, plateau (>1 log Week 4, >2 log Week 12) High chance of achieving SVR with PI Triple 2 1 Relapser Detection limit Rapid response High chance of SVR, no need for PI? Potential Time to reduce treatment duration with PI
6 On treatment failure rates during triple therapy according to prior response pattern 6 Telaprevir 57% 6 Boceprevir On treatment virologic failure % 8% 1% naiv REL P NR NULL %* 2% 9% Naiv Rel/Part NULL BT or stopping rule tx wk 24 or. wk 12 BT or stopping rule TVR wk 4,6,8 >1 /1 IU/mL entire tx. <2log wk 12/HCV RNA pos. wk 24 Bacon et al., NEJM 211; Poordad et al., NEJM 211 * PROVIDE Study, Vierling AASLD 211 Jacobson et al., NEJM 211; Zeuzem et al., NEJM 211
7 Individual viral kinetics during triple therapy patients with prior null response to Peg IFNa/Ribavirin Vertex 17 Study; Null Response = <1log wk. 4 / <2log wk. 12) 8 7 Viral kinetics during PEG IFNa/Riba 8 7 Viral kinetics during retreatment with triple therapy PEG/Riba + Telaprevir (TVR) 6 6 Log 1 (HCV RNA) Log 1 (HCV RNA) LOQ LOD 1 LOQ LOD Weeks Shiffman et al., AASLD 28 LOQ = Limit of quantification; LOD = Limit of Detection TVR + Peg IFN + RBV TVR stop Peg IFN + RBV Weeks
8 SVR rates according to treatment experience Peg IFNa/RBV PI Triple (BOC or TVR) Treatment naïve 38 44% 63 75% Relapser 24 29% 75 88% Partial responder 7 15% 52 59% Null responder 5% 33 4% Bacon BR. et al. N Engl J Med 211; 364: Bronowicki JP. et al. J Hepatol 212: 56: S6. Poordad F et al. N Engl J Med 211: 364: Sherman KE et al. N Engl J Med 211; 365: Jacobson IM et al. N Engl J Med 211; 364 : Zeuzem S. et al. N Engl J Med 211;364:
9 SVR rates according to treatment experience Peg IFNa/RBV PI Triple (BOC or TVR) Treatment naïve ~ 1.7 fold 38 44% 63 75% Relapser ~ 3 fold 24 29% 75 88% Partial responder ~ 4 fold 7 15% 52 59% Null responder ~ 6 fold 5% 33 4% Bacon BR. et al. N Engl J Med 211; 364: Bronowicki JP. et al. J Hepatol 212: 56: S6. Poordad F et al. N Engl J Med 211: 364: Sherman KE et al. N Engl J Med 211; 365: Jacobson IM et al. N Engl J Med 211; 364 : Zeuzem S. et al. N Engl J Med 211;364:
10 REALIZE (Telaprevir): SVR by HCV subtype and prior response to prior Peg IFN/RBV therapy Prior relapsers Prior partial responders Prior null responders 1b Pbo/PR48 Pooled T12/PR48 1a SVR (%) n/n= 1/34 119/142 6/31 123/14 3/16 26/55 1/1 27/4 1/17 24/88 1/2 22/59 HCV subtype 1a 1b 1a 1b 1a 1b Zeuzem S, et al. EASL 211. Abstract 2371
11 REALIZE (Telaprevir): SVR by baseline fibrosis stage and prior response to prior Peg IFN/RBV therapy Prior relapsers Prior partial responders Prior null responders Pbo/PR48 Pooled T12/PR48 SVR (%) n/n= 12/38 144/167 2/15 53/62 2/15 48/57 3/17 34/47 /5 1/18 1/5 11/32 1/18 24/59 /9 15/38 1/1 7/5 Stage No, minimal or portal fibrosis Bridging fibrosis Cirrhosis No, minimal or portal fibrosis Bridging fibrosis Cirrhosis No, minimal or portal fibrosis Bridging fibrosis Cirrhosis Zeuzem S, et al. EASL 211. Abstract 2371
12 RESPOND 2 (boceprevir): SVR by baseline fibrosis stage and prior response to Peg IFN/RBV Prior relapsers Prior partial responders Prior null responders PR48 BOC RGT BOC44/PR48 SVR (%) Excluded from RESPOND 2 n/n= 12/38 59/79 58/77 2/1 11/22 15/18 2/23 18/38 23/42 /5 3/1 6/13 Stage No, minimal or portal fibrosis (F F2) Bridging fibrosis / cirrhosis (F3/F4) No, minimal or portal fibrosis (F F2) Bridging fibrosis / cirrhosis (F3/F4) Bruno S, et al. J Hepatol 211;54(Suppl. 1):S4
13 Regimens in genotype 1 HCV infected prior relapsers without cirrhosis Telaprevir Telaprevir + Peg IFN + RBV Peg IFN alfa + RBV Stop treatment at Week 24 if undetectable at Week 4 and 12 Peg IFN alfa + RBV if detectable at Week 4 or 12 Boceprevir Peg/RBV lead in Boceprevir + Peg IFN + RBV Peg IFN + RBV Weeks Telaprevir EU SmPC; Boceprevir EU SmPC
14 CONCISE Interim Analysis: 12 week telaprevir (TVR) triple Treatment naïve or prior relapse HCV type 1 patients; IL28B CC (no cirrhosis) RVR (< 25 IU/mL, not detected Stop (N=57) (n=128) Telaprevir + Peg IFN + RBV Peg IFN + RBV (N=28) Weeks Nelson DR et al. J Hepatol 213 (Suppl) S37; #881 (EASL 213, poster)
15 CONCISE Interim Analysis: 12 week telaprevir (TVR) triple Treatment naïve or prior relapse HCV type 1 patients; IL28B CC (no cirrhosis) RVR (< 25 IU/mL, not detected Stop SVR4 96% (N=57) SVR12 89% (n=128) Telaprevir + Peg IFN + RBV Peg IFN + RBV (N=28) Weeks Nelson DR et al. J Hepatol 213 (Suppl) S37; #881 (EASL 213, poster)
16 Dosing duration in patients with partial or null response and/or with compensated cirrhosis TVR + Peg IFN + RBV Peg IFN + RBV >1 IU/mL: Stop all drugs >1 IU/mL: Stop all drugs Detectable: Stop Peg IFN/RBV Peg IFN + RBV BOC+ Peg IFN + RBV Cirrhosis and null response BOC+ Peg IFN + RBV Partial response Peg IFN + RBV 1 IU/mL: Stop all drugs Detectable: Stop all drugs Telaprevir EU SmPC; Boceprevir EU SmPC
17 Should we wait for better treatment options in treatment experienced patients (especially patients with null response?)
18 Peg IFNacontaining regimens Future HCV treatment strategies Phase III Treatment naive 2nd Gen. PI Triple Faldaprvir, Simeprevir NUC Triple Sofosbuvir HCV type 1 and 4 6 Next wave of triple/quadruple regimens Asunaprevir (PI) MK5172 (PI) MK79 (PI) Daclatasvir (NS5A) GS8558 (NS5A) Daclatasvir + Asunaprevir GS GS Phase III Next wave of all oral regimens Interferon free regimens NUC + RBV Sofosbuvir HCV type 2 and 3 ABT 45/r (PI/r)+ABT 267 (NS5A)+ABT 333 (NNUC)+RBV Faldaprevir (PI) + BI (NNUC) + RBV Daclatasvir (NS5A) + Sofosbuvir (NUC) ±RBV GS5885 (NS5A) + Sofosbuvir (NUC) + RBV GS9669 (Non NUC) + Sofosbuvir (NUC) RBV Asunaprevir (PI) + Daclatasvir (NS5A) + BMS PI = Protease Inhibitor, NUC = nucleosidic polymerase (NS5B) inhibitor, NS5A = NS5A Inhibitor, PI/r ritonavir boosted PI, RBV = Ribavirin
19 Can we better characterize nonresponder patients who are likely to respond?
20 Factors influencing antiviral response to direct antiviral acting agents (DAA) Genetics i.e. IL28B HCV Subtype (Viral load) Fibrosis stage Cirrhosis DAA Response Treatment Adherence (side effects) GGT Cholesterol Peg IFN/RBV Response
21 Virologic breakthough in protease inhibitor (PI) based Triple Therapy: Different Profiles Rapid breakthrough Early breakthrough Late breakthrough PI Triple PI Triple PI Triple Dual HCV RNA Detection limit Treatment duration (Weeks) Dual = Peg IFNa plus Ribavirin
22 Virologic breakthough in protease inhibitor (PI) based Triple Therapy: Different Profiles Typical phenotypes Rapid breakthrough Early breakthrough Late breakthrough HCV RNA PI Triple PI Triple PI Triple Dual Prior null response Prior partial response Liver cirrhosis Adherence? HCV subtype 1a IL28B non CC Detection limit Treatment duration (Weeks) Dual = Peg IFNa plus Ribavirin
23 Can we use the lead in phase to better predict treatment outcome in the individual?
24 RESPOND 2 (boceprevir): SVR according to IFN response at week 4 lead in 1 Poorly responsive to IFN (<1 log 1 HCV RNA decline at TW4) 1 Responsive to IFN ( 1 log 1 HCV RNA decline at TW4) SVR (%) SVR (%) BOC + 48 wk Peg IFNα 2b/RBV RGT BOC + Peg IFNα 2b/RBV Placebo + 48 wk Peg IFNα 2b/RBV BOC + 48 wk Peg IFNα 2b/RBV RGT BOC + Peg IFNα 2b/RBV Placebo + 48 wk Peg IFNα 2b/RBV Bacon BR, et al. N Engl J Med. 211;364:
25 Predictors for Boceprevir Triple response in patients with < 1 log HCV RNA decline during lead in Pooled data from Sprint 2 and Respond 2 SVR Rates 1 HCV Subtype 1 Fibrosis stage 1 HCV RNA a 1b F/1/2 F3/4 < 2Mio IU/ml > 2 Mio IU/ml Bacon B et al, AASLD 211, #33 (oral)
26 Telaprevir based triple therapy in patients with nonresponse or relapse: Evaluation of the lead in concept Previous relapse Previous partial or nonresponse Zeuzem S et al. N Engl J Med 211; 364: 2417
27 Predictors for Boceprevir Triple response in patients with < 1 log HCV RNA decline during lead in 1 8 Pooled data from Sprint 2 and Respond 2 SVR Rates according to week 8 virologic response (i.e. week 4 on triple therapy) 83 SVR rates % < >5 undetectable HCV RNA log decline at week 8 (week 4 on BOC) Bacon B et al, AASLD 211, #33 (oral)
28 SVR among telaprevir treated Patients with RVR and ervr, according to Previous Response (N=465) SVR for patients achieving RVR SVR for patients achieving ervr Patients (%) n/n= 183/21 38/56 28/42 183/193 38/55 27/38 Prior relapsers Prior partial responders Prior null responders Prior relapsers Prior partial responders Prior null responders Berg T et al. AASLD 211, #32
29 Role of Ribavirin?
30 Ribavirin reduces in vivo the mrna levels of a large number of ISGs (particularly those found up regulated in nonresponders to Peg IFNa/RBV) (Testoni et al, 211) RBV epigenetic reprogramming properties could synergize with anti HCV DAAs potent antiviral activity to restore the host innate immunity responses Testoni B et al. J Hepatol 213 (Suppl) S5, #11 (oral, EASL 213)
31 Ribavirin dose reduction during TVR Triple and early virologic response patterns (Treatment experienced pts with advanced fibrosis, N=25, HCV type 1) Ribavirin dose reduction W W4 W4 W12 No cevr 59% 83% 88% cevr in Nulls 44% 75% ND cevr in Hb < 12 g/dl vs. > 12 g/dl on treatment: 86% vs. 66% *EVR = early virologic response at week 12 Janczewska E et al. J Hepatol 213 (Suppl) S342; #816 (poster, EASL 213)
32 Conclusions Treatment experience per se is no unfavorable factor for treatment outcome using PI based triple regimens Highest chance for cure in patients with relapse and good partial response Highest chance for on treatment failure in null responders with HCV subtype 1a Cirrhosis High viral load Low LDL levels The individual value of lead in phase viral kinetics in order to predict who is going to respond to DAA regimens is questionable Regardless of the individual predictors, if RVR, chance for cure is high
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTreatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationUpdates on Current Status of HCV Therapy
Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of
More informationTreatment of chronic hepatitis C in drug-naïve patients
Treatment of chronic hepatitis C in drug-naïve patients 8th International Workshop on HIV & Hepatitis Co-infection Madrid, 31. May 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationMichael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY
Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA Kim Brown, MD Henry Ford Hospital Detroit, MI Michael Fried, MD University of North Carolina Chapel Hill, NC Jordan Feld, MD Toronto Western
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationBOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationEd Gane NZ Liver Transplant Unit Auckland City Hospital
Clinical Management of Hepatitis C Patients Treat Now or Wait Ed Gane NZ Liver Transplant Unit Auckland City Hospital SVR24 rates with PEG/RBV by HCV genotype Data from the real-world PROPHESYS cohort
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationSignificance of Hepatitis C. The Evolving Burden of Hepatitis C. The Bad News... The Good News... Chronic Hepatitis C Can be Cured
Journée scientifique de l'arl Yverdon, 24 mars 2011 Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois Université de Lausanne Significance of Hepatitis
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationHCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid Caveats on hepatitis C therapy decision making We treat persons with a liver. They
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationThe Scope of The Problem US Prevalence: 1.8% are chronically infected with Hepatitis C virus (HCV)
The Scope of The Problem US Prevalence: 1.8% are chronically infected with Hepatitis C virus (HCV) World Health Organization. Hepatitis C: Fact Sheet. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
More informationBest of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More information